Clinquest Revenue and Competitors

Boston, MA USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Clinquest's estimated annual revenue is currently $6M per year.(i)
  • Clinquest's estimated revenue per employee is $201,000

Employee Data

  • Clinquest has 30 Employees.(i)
  • Clinquest grew their employee count by -3% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$413.3M3240%$634MN/A
#2
$47.8M2380%N/AN/A
#3
$2.4M12-52%N/AN/A
#4
$25.7M12839%N/AN/A
#5
$12.9M64129%N/AN/A
#6
$23.9M1198%$113MN/A
#7
$0.3M30%N/AN/A
#8
$10.3M51-14%N/AN/A
#9
$1.8M367-4%$538MN/A
#10
$50M2493%N/AN/A
Add Company

What Is Clinquest?

Clinquest, Inc. is a Healthcare Product Development Service provider specializing in: • Vigilance Services for Medical Devices, Investigational and Marketed Products • Medical Information and complaint reporting • Drug/Device Development Consulting • Clinical Trial Implementation • Data Management and Biostatistics Through our in-house teams and alliances in the US and Europe, we can assemble Development teams or integrate into client project teams, providing oversight and expertise. For detailed information about the services Clinquest provides, please visit our website: www.clinquest.com, or read our informational summaries: http://tinyurl.com/3alz8b5 and http://tinyurl.com/2umg4mc.

keywords:N/A

N/A

Total Funding

30

Number of Employees

$6M

Revenue (est)

-3%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Clinquest News

2022-04-19 - ?? ??(PV) ?? ???-19 ?? ? 2029? ?? | Accenture ...

Accenture, Clinquest Group BV, Cognizant, Laboratory Corporation of America Holdings – Esports Today...

2022-04-17 - Pharmacovigilance (PV) Market Size 2022-2029| Key Players ...

Accenture; Clinquest Group B.v.; Cognizant; Laboratory Corporation Of America Holdings; Ibm Corporation; Arisglobal; Icon Plc. Capgemini; Itclinical; Imedglobal...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.5M30-9%N/A
#2
$6.1M303%N/A
#3
$5.6M32N/AN/A
#4
$5.8M3210%N/A
#5
$6.9M3210%N/A